Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Idifarma Set to Meet EU FMD Regulations | Contract Pharma

What are you searching for?

Sign in
Videos

Idifarma Set to Meet EU FMD Regulations

In preparation for EU Falsified Medicines Directive’s February 2019 deadline for the serialization of licensed drug products

By: Betsy Louda

, Contract Pharma

Idifarma has confirmed that it is officially ready to meet forthcoming EU serialization regulations.

Following a €200k investment, the Antares Vision Print&Check EVO-TE carton serialization station is now installed and fully operational at Idifarma’s EU-GMP approved plant in Pamplona, Spain.

The announcement comes ahead of the EU Falsified Medicines Directive’s (EU FMD) February 2019 deadline for the serialization of licensed drug products.  

Luis Oquiñena, general manager and co-founder of Idifarma said, “Supporting our customers to meet new regulatory requirements and combat counterfeit medicines is very important to us. We have worked closely with our customers, the manufacturers of this machine and track and trace software vendors like TraceLink to ensure that our capabilities meet both existing and potential new clients’ needs. This machine offers us the flexibility to upgrade for future regulatory or client requirements and will enable us to help protect our clients’ products and the public against counterfeit pharmaceuticals.”

The industry-wide EU FMD regulation is a legal requirement for all pharmaceutical companies intended to improve traceability of drugs, help in the fight against counterfeit products entering the supply chain and ultimately improve patient safety. 

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters